BCAL Diagnostics Issues 62 Million Shares
BCAL Diagnostics Limited (AU:BDX) has released an update.
BCAL Diagnostics Limited has announced the issuance of 62 million shares to sophisticated investors at $0.10 each, under the Corporations Act without the need for a disclosure. The company confirms compliance with all necessary legal provisions and states there is no undisclosed ‘excluded information’ at the time of notice. BCAL Diagnostics is an innovative Australian firm focused on the early detection of breast cancer through non-invasive blood testing.
For further insights into AU:BDX stock, check out TipRanks’ Stock Analysis page.
TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.